Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial

Lancet

Volumn 357, Issue 9271, 2001, Pages 1842-1847

  Chaudhari, U ^a   Romano, P ^a   Mulcahy, L D ^b   Dooley, L T ^b   Baker, D G ^b   Gottlieb, A B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANALYSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0035832515     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04954-0     Document Type: Article

References (34)

1. Treatment of psoriasis
2. The economic impact of psoriasis increases with psoriasis severity
3. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial
4. Psoriasis
5. The pathogenesis of psoriasis: Immunological facts and speculations
6. Immunopathogenesis of psoriasis
7. The immunology of psoriasis
8. Aetiology and pathogenesis of psoriasis
9. Psoriasis: Immunopathology and immunomodulation
10. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions
11. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory disease
12. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
13. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
14. Severe psoriasis: Oral therapy with a new retinoid
15. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
16. Results of a single-dose, dose-escalating trial of anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis
17. Immunopharmacologic effects of Amevive (LFA3TIP) in chronic plaque psoriasis: Selectivity for peripheral memory-effector (CD45RO+) over Naïve (CD45RA+) T cells: AMEVIVE Clinical Study Group
18. Successful in vivo blockage of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
19. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathway of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
20. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach
21. IL-11 is an immune-modulatory cytokine which downregulates IL-12, Type 1 cytokines, and multiple inflammation-associated genes in patients with psoriasis
22. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
23. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
24. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion
25. New comparisons of two types of TNFα antagonists approved for rheumatoid arthritis
26. Tumor necrosis factor
27. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization
28. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
29. Effect of TNFα blockade on synovial histology in spondyloarthropathy
30. Very rapid anti-inflammatory effect of anti-TNF-α (Remicade™) in Crohn's disease as assessed by 99MTC-WBC-scintigraphy
31. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
32. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation of Crohn's ileocolitis
33. Increased peripheral production of TNF-α and mucosal levels of activated NFκB predict relapse after treatment with infliximab in patients with Crohn's disease
34. Decreased mucosal lymphocyte proliferation following treatment with infliximab in Crohn's disease